Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol in Cirrhosis Patients With Uncomplicated Ascites
NCT05057572Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of carvedilol in Liver cirrhosis (LC) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Incidence of complicated ascites (refractory ascites, SBP, AKI-HRS) at 1 year. Started Oct 2021; status: completed.
02
Drugs
carvedilol
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT05057572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057572.